Circulating fatty acid binding protein 4 (FABP‐4) concentrations and mortality in individuals with colorectal cancer in the European Prospective Investigation into Cancer and Nutrition study
Authors
- Thu Thi Pham
- Katharina Nimptsch
- Krasimira Aleksandrova
- Mazda Jenab
- Veronika Fedirko
- Anja Olsen
- Anne Tjønneland
- Claire Cadeau
- Gianluca Severi
- Matthias B. Schulze
- Renée Turzanski Fortner
- Verena Katzke
- Claudia Agnoli
- Carlotta Sacerdote
- Rosario Tumino
- Simona Signoriello
- Camino Trobajo-Sanmartín
- Jesús-Humberto Gómez
- Maria-Dolores Chirlaque
- Maria Jose Sánchez
- Marta Crous-Bou
- Anne May
- Alicia K. Heath
- Dagfinn Aune
- Elisabete Weiderpass
- Tobias Pischon
Journal
- International Journal of Cancer
Citation
- Int J Cancer
Abstract
Human fatty acid binding protein-4 (FABP-4), a protein elevated in obesity that promotes colon cancer cell invasiveness and metastasis, may be associated with higher mortality in individuals with colorectal cancer (CRC) and may serve as a mediator of the obesity–mortality association in these individuals. We used a causal diagram to inform covariate selection and applied Cox proportional hazards models to estimate hazard ratios (HRs) for CRC-specific, non-CRC-specific, and all-cause mortality by FABP-4 levels measured in baseline blood samples from 1371 incident CRC cases from the European Prospective Investigation into Cancer and Nutrition cohort. Competing risk analyses were adapted for CRC and non-CRC deaths. Mediation analyses were conducted to estimate total effects (TEs), direct effects (DEs), and mediation proportions (MPs) by FABP-4 of pre-diagnostic body mass index (BMI) on mortality. In the fully adjusted model including BMI, higher circulating FABP-4 concentrations were associated with higher CRC mortality (HR(Q4vsQ1) = 1.49; 95% CI: 1.11–2.00) and all-cause mortality (HR(Q4vsQ1) = 1.49; 95% CI: 1.15–1.93), but not statistically associated with non-CRC mortality (HR(Q4vsQ1) = 1.51; 95% CI: 0.82–2.76). The TE and DE per 5 kg/m(2) of BMI on all-cause mortality were 1.21; 95% CI: 1.10–1.34, and 1.13; 95% CI: 1.02–1.26, respectively, with a MP of 34.5% (p = .002) by FABP-4. For CRC-specific and non-CRC-specific mortality, MPs by FABP-4 were 33.7% (p = .03) and 36.1% (p = .02), respectively. In conclusion, higher concentrations of FABP-4 were associated with higher CRC-specific and all-cause mortality in individuals with CRC. FABP-4 was a significant partial mediator of the adiposity-mortality relationship in individuals with CRC.